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INTRODUCTION
Metabolite-in-safety testing and the attainment of safe and efficacious drug use are key concerns in the drug development/surveillance paradigm. There has been a resurgence of interest on the testing of metabolites that are mediators of drug activity and toxicity due to the improvement in analytical methods for their detection, isolation, and characterization (Baillie et al., 2002) . Metabolite testing is recommended, especially when metabolites are unique and identified only in humans, or when the metabolite exists at disproportionately higher levels in humans (>10%) than the animal species that was used for standard, nonclinical toxicology testing (Naito et al., 2007 ; FDA Guidance for Industry Safety Testing of Drug Metabolites, 2008) . It has been proposed that a metabolite is considered as a major metabolite when the metabolite represents >10% (Davis-Bruno and Atrakchi, 2006) , or 25% exposure of the precursor (Baillie et al., 2002) . Others had suggested the estimate to be based on unbound concentration in the circulation or amounts in the excreta (Smith and Obach, 2005) . When the "% exposure" is based on total radioactivity, the parameter is time-dependent, and may not be a reliable estimate when the metabolite in question is readily metabolized to other metabolites.
Many commentaries suggest that the definition of the % exposure or amount may not be the key issue. Rather, testing needs to be appraised case-by-case (Hastings et al., 2003; Humphreys and Unger, 2006; Naito et al., 2007 ; FDA Guidance for Industry Safety Testing of Drug Metabolites, 2008) .
Obviously, it is virtually impossible to synthesize reactive or unstable metabolites for the proper characterization of toxicity. Suffice to say, the metabolite must be stable. An important question for stable, synthetically-prepared metabolite is how to administer the in order to mimic exposure of the formed metabolite. Would the time-course and AUC of the This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on October 23, 2008 as DOI: 10.1124 at ASPET Journals on April 13, 2017 dmd.aspetjournals.org Downloaded from preformed metabolite be similar to the time-course and AUC of the formed metabolite and mimic metabolite exposure from precursor drug administration?
The ADME properties of the precursor drug and metabolite would need to be considered for metabolite kinetics. Our laboratory had employed perfused organ approaches to examine metabolite kinetics in the liver (deLannoy et al., 1993) and kidney (Geng et al., 1996) after administrations of both the drug and preformed metabolite. Differences were found between the fates of the generated and preformed metabolites upon solving for the AUC of the formed vs. the preformed metabolite (Pang et al., 2008) . Transporters and enzymes of the parent drug and metabolite were found to be important variables that determine the AUC of the formed metabolite, AUC{mi,P}. But the drug parameters were absent regarding the AUC of the preformed metabolite, AUC{pmi}, in both the liver and kidney.
The theoretical examination of metabolite disposition has not been extended to the intestine, although there has been development on modeling of transporters and/or enzymes for drug absorption (Cong et al., 2000, Kothare and Zimmerman 2002) . In this tissue, apical absorptive transporters bring molecules into the enterocyte whereas apical efflux transporters are capable of secreting the absorbed drug back to the lumen, and the drug in tissue is subject to biotransformation before it enters the circulation at the basolateral membrane, either passively or via efflux transporters (Pang, 2003) . The net outcome of the events constitutes intestinal drug absorption.
In this communication, we tested the hypotheses that precursor and metabolite parameters influence the kinetics of the formed metabolite, and that differences exist between preformed and formed metabolite kinetics in the intestine. Two physiologically-based pharmacokinetic (PBPK) models are used. The traditional physiological model (TM) ( Figure 1A ) has identified parameters This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on October 23, 2008 as DOI: 10.1124 at ASPET Journals on April 13, 2017 dmd.aspetjournals.org Downloaded from of gastrointestinal transit, intestinal flow, and intestinal transporters and enzymes as variables that regulate the ultimate absorption of orally administered substrates. The segregated flow model (SFM) suggests that a minor proportion of the intestinal flow perfuses the enterocyte region that mediates absorption, metabolism, and efflux, and a larger flow perfuses a non-metabolizing (inert) serosal tissue ( Figure 1B ). Both models are presently extended to describe metabolite kinetics so as to identify parameters that would affect the AUC of the formed and preformed metabolites for oral and intravenous administration. The SFM is necessary to explain the greater extent of intestinal metabolism that is associated with oral dosing compared to systemic dosing.
This route-dependent, intestinal metabolism was observed for morphine (Cong et al., 2000) and other substrates in both animals and man (Pang, 2003) . Not unlike the SFM, SimCYP®, the simulation program, uses a strategy based on a reduced villous flow and not total intestinal flow for the prediction of intestinal clearances (Yang et al., 2007) .
This article has not been copyedited and formatted. The final version may differ from this version. 
METHODS
The TM and SFM models are physiologically-based models that have been introduced to relate flow, volume, transporters that mediate absorption, distribution and secretion, and enzymes for metabolism ( Fig. 1) (Cong et al., 2000) . The need for comparing metabolite kinetics for the TM and SFM is based on the superiority of the SFM in explaining route-dependent intestinal metabolism, that less drug is metabolized with intravenous vs. oral drug administration (Cong et al., 2000) . This concept was also adopted by SimCYP ® in the modeling of intestinal clearances with a villous flow (Q villi ) which is lower compared to the total intestinal flow (Yang et al., 2007) .
For the TM, the total intestinal blood (Q I ) perfuses the entire intestinal tissue; the transfer intrinsic clearances for the transport of precursor (P) between blood and tissue at the basolateral membrane are described by CL d2 and CL d1 , representing the summation of passive and transporter-mediated pathways. In tissue, metabolism (intrinsic clearance, CL int,met,I ) to form the primary metabolite, Mi, and apical secretion into the lumen (secretory intrinsic clearance, CL int,sec,I ) are available elimination processes (Fig. 1A) . In the lumen, the precursor drug may be absorbed (rate constant, k a ) or leave the lumen irreversibly via gastrointestinal transit or degradation (rate constant, k g ). The fraction of dose absorbed, F abs , is given by k a /(k a +k g ) and describes the net extent of intestinal absorption into the intestinal tissue.
For the SFM, the intestinal blood flow is segregated, with a lower flow (Q en , 10% total intestinal flow) perfusing the enterocyte region that consists of apical and basolateral transporters and metabolic enzymes. The remaining, seroal flow (Q s , 90% flow) perfuses a non-metabolizing or inert region (serosa, submucosa and part of the mucosa) (Cong et al., 2000) (Fig. 1B) .
Subscripts enb, en, sb, and s, denoting enterocyte blood, enterocyte tissue, serosal blood, and (Fig. 1) . A similar set of parameters exists for the metabolite. The parameters of the precursor are not qualified, whereas those for the metabolite are qualified by {mi}; those pertaining specifically for the preformed and formed metabolites are further classified by {pmi} and {mi,P}, respectively.
These models were utilized to build concepts on metabolite kinetics. For simplicity, the intestine was assumed to be the only tissue for metabolism, secretion, as well as absorption, and PBPK modeling was based on the perfused rat intestine preparation. Binding of the drug and metabolite was assumed as non-existent (unbound fractions = unity), and it was assumed that the P formed only one primary metabolite (Mi), which underwent further metabolism and secretion in the intestine (Fig. 1) . It was assumed that activities for absorption (k a {mi}), luminal degradation and gastrointestinal transit (k g {mi}), transport (CL d1 {mi}, CL d2 {mi}, C Ld3 {mi}, and CL d4 {mi}), secretion (CL int,sec,I {mi}) and metabolism (CL int,met,I {mi}) are identical for both preformed and formed metabolites.
Rate-equations pertaining to the rates of change of precursor and metabolite were presented in the Appendix under linear conditions. The coefficients were used for matrix inversion by the program, Maple9 ® (Waterloo Maple Inc., Waterloo, Canada). The solutions provided the areas under the concentration time curve of the preformed (AUC{pmi}) and formed (AUC{mi,P}) primary metabolites after administration of the synthetic metabolite and precursor drug (doses of 100 units into a reservoir volume of 200 ml and luminal volume of 2 ml), respectively. Accordingly, the unit of metabolite concentration in the reservoir is dose unit/ml This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
The following solutions for AUC{mi,P} and AUC{pmi} for intravenous (subscripted iv) or oral (subscripted po) administration of the precursor and preformed metabolite, respectively, for the TM and SFM were obtained from matrix inversion by Maple ® .
(1)
The above equations for the formed metabolite were found to differ from those for the preformed metabolite when doses of the performed metabolite (Dose{pmi}} or precursor (Dose) were given intravenously (iv) or orally (po) ( Table 2) . It was also noted in all of the above solutions that the CL int,sec,I and CL int,sec,I {mi} terms were effectively reduced by (1-F abs ) and (1-F abs {mi}), AUC iv {pmi}, AUC po {pmi} and F{pmi} after administration of preformed metabolite.
The drug parameters: CL int,met,I , CL int,sec,I , CL d1 , CL d2 , k a , and k g , were absent in the solutions for the preformed metabolite, AUC iv {pmi} and AUC po {pmi} (Eqs. 1 to 3). The AUC po {pmi} for the TM and SFM was identical, whereas differences existed for AUC iv {pmi} due to difference in the flow terms: Q I for TM and Q en for the SFM (Eqs. 1 and 2), as described previously by Cong et al. (2000) . Since the flow terms were absent in the solution for AUC po {pmi}, the same solution (Eq.
3) existed for the TM and SFM.
Simulations that were based on Eq. 1 and 2 revealed similar profiles for AUC iv {pmi} for the TM and SFM, when CL int,met,I {mi} and CL int,sec,I {mi} were altered. The resulting AUC iv {pmi} was lower for the TM due to the higher flow rate (Q I > Q en ) (Fig. 2) . Increasing CL int,met,I {mi} or CL int,sec,I {mi} decreased the AUC iv {pmi}, and the effect was greater for the TM than the SFM.
Comparatively speaking, CL int,met,I {mi} reduced AUC iv {pmi} more so than CL int,sec,I {mi} for both the TM ( Figs The metabolite that was secreted into the lumen was subject to reabsorption, rendering higher AUC iv {pmi}s with high k a {mi}s, regardless of whether the preformed metabolite was given This article has not been copyedited and formatted. The final version may differ from this version. orally or intravenously (Fig. 3 ). This effect explained why there were greater changes associated with CL int,met,I {mi} than with CL int,sec,I {mi} for both iv ( AUC iv {mi,P} and AUC po {mi,P} after administration of precursor drug. Solutions for AUC iv {mi,P} the formed metabolite for the TM were identical to that of the SFM (Eq. 4). The same comment also applied to AUC po {mi,P} (Eq. 5). These areas of the formed metabolite (AUC iv {mi,P} and AUC po {mi,P}) arising from precursor administration were further affected by precursor drug parameters for metabolism and secretion (CL int,met,I and CL int,sec,I ), and the fraction of precursor dose absorbed (F abs ). In addition, AUC iv {mi,P} and AUC po {mi,P} were also modulated by metabolite parameters: k a {mi} and k g {mi} that affect F abs {mi}, the metabolite This article has not been copyedited and formatted. The final version may differ from this version. (Table 2) .
Comparison of AUCs of the metabolites. The solutions of the AUCs of the formed and preformed metabolites allowed a comparison of the areas for the TM and SFM with respect to different routes of administration ( Table 2 ). The ratios of areas for the formed to preformed metabolite after iv and po administration of precursor and preformed metabolite,
[AUC iv {mi,P}/AUC iv {pmi}] and [AUC po {mi,P}/AUC po {pmi}], were not unity (Table 2) .
F{pmi}, given by the ratio, [AUC iv {mi,P}/AUC iv {pmi}], exhibited different sensitivities to the metabolite parameters for the TM and SFM; this was again due to the flow terms Q I and Q en . The area ratio of AUC po {mi,P}/AUC iv {mi,P} for both TM and SFM yielded a simplified F abs Dose po /Dose iv and was reduced to F abs or [k a /(k a +k g )] when equal precursor doses were administered (Table 2) .
This article has not been copyedited and formatted. The final version may differ from this version. on the concentration-time profiles of the preformed (Fig. 8) and formed (Fig. 9 ) metabolites.
Simulations for the preformed metabolite after its iv administration revealed a faster decay profile for preformed metabolite for the TM when compared to the SFM (Figs. 8A) . This is expected due to the greater intestinal clearance based on Q I and not Q en , yielding a lower AUC iv {pmi} for the TM. With po dosing, the peak concentration of the preformed metabolite was lower according to the SFM and this occurred at almost the same time as that for the TM; the decay t 1/2 of the metabolite for the SFM was also longer. The TM metabolite profile crossed over that of the SFM, and the AUC po {pmi}s for both the TM and SFM were identical. The pattern existed for all CL d {mi} values of the metabolite. Poor transfer characteristics of the metabolite into the enterocyte transformed the decay profile to yield a protracted t 1/2 , showing the strong influence of the metabolite transfer clearances (cf. Figures 8A and 8B ). Under the condition of poor metabolite entry, there was virtually no difference in the decay profiles of the preformed metabolite between the TM and SFM. Note also that the t 1/2 s for the iv and po cases for the TM or SFM were parallel (Fig. 8) .
Profiles of the formed metabolite were found to alter with the absorption rate constant of the precursor, k a, and the metabolite transfer clearance, CL d {mi} (Fig. 9) . At high CL d {mi} and low absorption rate constant (k a = 0.01 min -1 ), levels of the formed metabolite for the TM and the SFM after iv precursor administration were generally higher than those after po dosing. At high CL d {mi} and high k a (1 min -1 ), the concentration-time profiles of the metabolite edged closer for both iv and po precursor doses, although the metabolite profiles after po peaked earlier than those This article has not been copyedited and formatted. The final version may differ from this version. for iv (Fig 9B) . At low CL d {mi}s, however, only upswing profiles were observed for the simulated cases at both the low (0.01 min -1 ) and high (1 min -1 ) k a s (Figs. 9C and 9D ). The metabolite profiles after iv precursor administration were comparatively higher than those for oral dosing of precursor that exhibited poor absorption (k a = 0.01 min -1 ) (Fig. 9C) . With good precursor absorption (k a = 1 min -1 ), all metabolite profiles became comparable (Fig. 9D ) when reabsorption reclaimed most of the secreted precursor. Generally speaking, the formed metabolite peaked earlier and higher with increasing k a , since a faster precursor absorption rate not only increased the rate of drug delivery to intestinal enzyme sites but also reduced effectively the secretory intrinsic clearance, CL int,sec,I (see Table 2 ). Because AUC iv {mi,P} is identical for the TM and SFM, the metabolite curves eventually crossed over, and the AUC iv {mi,P}s became identical (Fig. 9) ; the same occurred for AUC po {mi,P}.
Simulations based on equivalent preformed metabolite dose. One strategy was formulated to estimate the dose equivalent of the preformed metabolite that would yield an AUC{pmi) identical to the AUC{mi,P} (precursor Dose = 100 units). From Table 2 , the required doses, Dose iv {pmi} and Dose po {pmi}, can be calculated.
For the TM, iv case ( 
This article has not been copyedited and formatted. The final version may differ from this version. showed profiles that were similar to those in Fig. 10 , although the metabolite concentrations were lower (simulations not shown).
DISCUSSION
The aspect on drug safety impacts on preclinical and clinical stages in drug development and extends to the time when the drug is in the market place. In vitro testing and in vivo pharmacokinetics either in animals or in man is of paramount importance. These include in silico testing, high throughput systems that are enzyme-or cell-based, including microfluidic systems of multiple cells in culture (Leeder et al., 1989; Johansson et al., 2004; Kehtani and Bhatia, 2006; Li, 2007) , and identification of mechanisms of on-target and off-target toxicity via covalent binding, alkylation protein, DNA (Baillie, 2006) or downstream adducts, biomarkers, or mechanism-based inactivation of cytochrome P450s (Jones et al., 2007) . Animal models and surrogate animal testing are utilized for investigation of metabolite-mediated toxicity, genotoxicity studies, toxicity testing of embryonic-fetal development, and carcinogenicity studies in toxicological testing (Stevens, 2006; Lee and Dordick 2006) . In cases where metabolite exposure has been inadequately assessed, it is proposed that synthesized reference standard may need to be prepared and the safety of the metabolite assessed using a route of administration whereby adequate exposure can be obtained in an appropriate species (FDA Guidance, 2008) .
The recent 2008 FDA guidance on metabolite safety defined a major metabolite as 10%.
It is unknown whether this value is based on the percent of total radioactivity in serum, excreta, dose, or the AUC of the parent drug. The estimate of the metabolite amount is imprecise even with use of a radioactivity dose, since the value is time-dependent and reliant on the eliminatory pathways of the metabolite. The latter method necessitates consideration of a sound estimate for the volume of distribution of the metabolite. This distribution volume of the formed metabolite may or may not be identical to that obtained from administration of the preformed metabolite. Moreover, metabolite testing has been proposed, even though it has This article has not been copyedited and formatted. The final version may differ from this version. Pang et al., 2008) . A reverberating theme that came through is that the safety assessment of metabolite should be a case-by-case approach (Kastings et al., 2003; Naito et al., 2007 , FDA Guidance, 2008 .
If metabolite testing is mandated in animal testing or man, an inevitable question is how to administer the metabolite, systemically or orally. From a theoretical standpoint, there is the need to consider the SFM in addition to the TM for intestinal modeling, since many drugs are shown to exhibit intestinal route-dependent metabolism (Pang, 2003) . A similar strategy was utilized by the SimCYP ® group to describe intestinal clearances (Yang et al., 2007) . Therefore, we felt compelled to compare the results on AUC{mi,P} for both the TM and the SFM, expecting to see higher AUC iv {pmi} for the SFM due to the flow differences, Q en for the SFM and Q I for the TM (Table 2) . We showed that formed and preformed metabolite kinetics and time-courses differed in the intestine, and these were dependent on the route of administration and flow patterns (Q I vs. Q en ) of the intestine (Figs. 2 to 10 ). The AUC po {pmi} were identical for both models. Moreover, identical AUC{mi,P}s were found for the TM and SFM for iv precursor administration, and the same applied to po administration as well. The time courses of the formed metabolite were found to differ with different k a of the precursor (Fig, 9) . Even when "area-equivalent" preformed metabolite oral doses were given, the correspondence between the formed and preformed metabolite levels was poor, especially for the early time points (Fig. 10) .
The results showed that, in consideration of intestinal elimination only, the resulting AUC{pmi} was affected only by the absorptive, distributional and eliminatory characteristics of This article has not been copyedited and formatted. The final version may differ from this version. AUC{pmi} for the oral and intravenous cases for both models ( Table 2 ). The same was found in the liver and kidney. The areas under the curve of the formed metabolite were influenced by distributional and eliminatory characteristics of both the precursor and metabolite in the organ, suggesting that metabolite administration will lead to kinetic observations that deviate from those of the preformed metabolite (Pang et al., 2008) . Indeed, evidence on different kinetics between the formed species was found to exist in the liver (Xu et al., 1990; deLannoy et al., 1993) , kidney (Geng et al., 1996) , and intestine (Cong et al., 2000) .
The time-course of the toxic, formed metabolite and its AUC{mi,P} would be influenced by distributional and eliminatory characteristics of the metabolite in the intestinal tissue, and those for the precursor (Figs. 8 to10) , the route of administration and whether a partial or total flow perfuses the enterocyte region (TM vs. SFM). The notion that exposure of the metabolite is reproducible by administration of the preformed metabolite is not attainable, and there was practical limitations in this approach. The same was implied in a commentary by Smith and Obach (2006) . However, the argument of %exposure vs. absolute amount (Baillie et al., 2002; Smith and Obach, 2005; ) is immaterial and irrelevant in providing any clearer answers.
More relevant is how to mimic the kinetics and toxicity of the metabolite in question.
The theoretical examination has alluded to the dilemma in metabolite toxicity testing with testing of synthetic metabolites. There are additional features that can modulate metabolite AUCs presented in this theoretical treatise. First, the heterogeneous distribution of transporters and enzymes along the segment of the small intestine has been shown to influence drug bioavailability (Pang, 2003; Tam et al., 2003 , Liu et al., 2006 Although metabolite administration/testing would not directly reflect the time course of the formed metabolite, the data may be utilized favourably. The available preformed metabolite data may be wisely incorporated into a combined PBPK model of the precursor-metabolite to improve the predictions on metabolite behavior resulting from drug administration. This kind of strategy is utilized frequently in risk assessment. The administration of a metabolite, iv or po, had aided in the modeling and prediction of the formation of toxic metabolites as well as targeted toxicity outcomes. Examples of these elegant works include modeling of the metabolism of styrene oxide from styrene on respiratory tract toxicity (Sarangapani et al., 2002) , the metabolism and enterohepatic circulation of di-n-butylphthalate to the monobuytlphate and the glucuronide, compounds that cause impairment of male reproductive tissues (Clewell et al., 2008) , the metabolism and oral absorption and of atrazine on toxicity of the pituitary axis and enzyme inhibition (McMullin et al., 2007) , the metabolism-associated toxicities of trichloroethylenes (Dobrev et al., 2002) , the bioactivation of vinyl chloride to the DNA-reactive epoxide (Chen and Blancato et al., 1989; Reitz et al., 1996; Clewell, 2001) , and the inhalation toxicity of acrylate ester (Frederick et al., 1998; Sweeney et al., 2004 
Legends
Figure 1. Schematic depiction of drug (D) and metabolite (M) behaviors in the TM (A) and SFM (B)
. For TM, the intestinal blood (Q I ) perfuses the entire intestinal tissue, the site of metabolism and absorption from the lumen. For SFM, intestinal blood is segregated to perfuse the nonmetabolizing (Q s ) and enterocyte-mucosal (Q en ) regions. For the oral route of administration, the entire oral dose passes through the enterocyte region for both TM and SFM. For intravenous or systemically delivered species, the total flow (Q I ) perfused the intestine tissue and enterocyte region for TM, but there is only partial flow (Q en ) reaching the enterocyte region for the SFM. The drug equilibrates with those in the corresponding tissue layers with intrinsic transfer clearances CL d1 and CL d2 for TM , or CL d1 and CL d2 , CL d3 and CL d4 for SFM. Subscripts enb, en, sb, and s denote enterocyte blood, enterocyte region, serosal blood and serosal region, respectively. The absorptive, metabolic and efflux activities within the villus tips of the mucosal layer are represented by the rate constant, k a , and metabolic and secretory intrinsic clearances, CL int,met,I and CL int,sec,I , respectively. Gastrointestinal transit or degradation rate constant in the lumen is denoted by k g . A similar set of parameters exist for the metabolite, qualified by {mi}. Figure 2 . The area under the curve of the preformed metabolite after systemic administration, AUC iv {pmi}, for the TM (A,C) and SFM (B,D) against the CL int,met,I {mi} and CL int,sec,I {mi} for CL d1 {mi}=CL d2 {mi}= 2 ml/min (A,B) or 0.01 ml/min (C,D). The AUC iv {pmi} for TM was lower than that for SFM because of the flow terms, Q I for the TM and Q en for the SFM (Eqs. 1 and 2). Note that AUC iv {pmi} was strongly modulated by CL int,met,I {mi} and not CL int,sec,I {mi}. For this simulation, CL d2 {mi} was set as identical to CL d1 {mi}, i.e., CL d2 {mi}/CL d1 {mi} = 1. The influence of CL int,sec,I {mi} was much less than those of CL int,met,I {mi}; (B) the effects of CL int,sec,I {mi} was neutralized by k a {mi}; (C) AUC po {pmi} was affected directly by the ratio of CL d2 {mi}/CL d1 {mi}. Figure 5 . The systemic availability F{pmi}, given by AUC po {pmi}/AUC iv {pmi}, for the TM (A,C) and SFM (B,D) against the CL int,met,I {mi} and CL int,sec,I {mi} for CL d1 {mi} = CL d2 {mi} = 2 ml/min (A,B) or 0.01 ml/min or (C,D). The F{pmi} for TM was higher than that for SFM because of the flow terms, Q I for the TM and Q en for the SFM (Eqs. 1 and 2). Note that AUC iv {pmi} was strongly modulated by CL int,met,I {mi} and not CL int,sec,I {mi}. For this simulation, CL d2 {mi} was set as identical to CL d1 {mi}, i.e., CL d2 {mi}/CL d1 {mi} = 1. (Table 1) : CL d {mi} = 2 ml/min (A), or 0.01 ml/min (B), with doses of 100 units for the preformed metabolite; k a {mi} = 0.05 min -1 ; reservoir and lumen volumes of 200 and 2 ml, respectively. The initial concentration of preformed metabolite in the dosing compartment (reservoir) is 0.5(dose unit/ml) for the iv cases and 50 (dose unit/ml) in the intestinal lumen for po cases. Other parameters of the preformed metabolite used for simulation were shown in Table  1 . (A) The graphs differed for CL d {mi} = 2 ml/min (A) and CL d {mi} = 0.01 ml/min (B). At high CL d {mi}, the t 1/2 for the TM (iv and po) was faster than that for the SFM (iv and po) (A) At low CL d {mi}, the graphs were identical for TM and SFM after iv or po dosing of the preformed metabolite (B). (Table  1) : CL d {mi} = 2 ml/min for Case 1A (A) and Case 1B (B); and CL d {mi} = 0.01 ml/min for Case 2A (C) and Case 2B (D), and k a {mi} = 0.05 min -1 , with doses of 100 units for precursor. Since the reservoir and lumen volumes were 200 and 2 ml, respectively, the initial concentration of precursor in dosing compartment is 0.5 (dose unit/ml) in reservoir for the iv cases and 50(dose unit/ml) in intestinal lumen for po cases. Other parameters of precursor and metabolite used for simulation were shown in Table 1 . The metabolite curves were different for k a = 0.01 min -1 (A) and (C) vs. k a = 1 min -1 (B) and (D). Higher (formed) metabolite levels were observed with higher k a and higher CL d {mi}. The absorptive constant, k a , also influenced the time course/profile of the formed metabolite by reducing the effective secretion intrinsic clearance (CL int,sec,I ), thereby increasing the rate of drug metabolism. Figure 10 . Simulation of the time courses of formed metabolite (profiles) for Cases 1 and 2 (similar to those of Figure 9 ). CL d {mi} = 2 ml/min for Case 1A (A) and Case 1B (B), and CL d {mi} = 0.01 ml/min for Case 2A (C) and Case 2B (D); and k a {mi} = 0.05 (dose unit/ml). The precursor dose of 100 units was used, whereas the dose of the preformed metabolite was estimated with Eq. 8, such that AUC po {mi,P} = AUC po {pmi}. Note again that higher levels of the metabolites were observed with higher k a and higher CL d {mi}. The concentration profiles of the preformed metabolite were consistently higher than those of the formed metabolite for the TM or SFM, especially at the earlier time points, although the areas under the curve of the preformed and formed metabolites were identical. In the following section, P denotes the concentration of the precursor, whereas Mi denotes the concentration of the metabolite, either preformed ({pmi}) or formed from the administration of the precursor ({mi,P}). V denotes the volume in each compartment, f, the unbound fraction; subscripts: I, R, intb, int, and lumen denote the intestine, reservoir, intestinal blood, intestinal tissue, and intestine lumen, respectively.
Subscripts, s, sb, en, and enb, describe the serosal, serosal blood, enterocyte, enterocyte blood, respectively. Q I describes the total intestinal blood flow rate, or sum of the blood flows perfusing the enterocyte layer (Q enb , 10% of Q I ) and the serosal layer (Q sb , 90% of Q I ). The parameters pertaining to the metabolite are qualified by {mi}. Definition of the kinetic parameters has been given in the Methods Section.
I. TM: preformed metabolite
Rate of change of metabolite in reservoir,
Rate of change of metabolite in intestinal blood, Matrix for the TM model: preformed metabolite
Rates of change of precursor and metabolite in reservoir,
Rates of change of precursor and metabolite in intestinal blood,
Rates of change of precursor and metabolite in intestine tissue,
Rates of change of precursor and metabolite in intestine lumen,
